Home > Insider Trading > Filing (0001104659-23-093468)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1442836	Mersana Therapeutics Inc.	MRSN	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1877233	Tushar Misra	C/O Mersana Therapeutics, Inc. 840 Memorial Drive Cambridge MA 02139	Svp, Chief Manuf. Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-08-16	6,250	$0.00	13,415	No	4	M	Direct
Common Stock	Disposition	2023-08-17	1,908	$1.18	11,507	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Unit	Disposition	2023-08-16	6,250	$0.00	6,250	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
12,500			No	4	M	Direct

Footnotes

Represents shares of common stock received upon vesting of a portion of the restricted stock units ("RSUs") awarded to the Reporting Person on August 16, 2021.
Includes 1,235 shares of common stock acquired on June 15, 2023 by the Reporting Person through the Issuer's employee stock purchase plan.
Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2023. The sale was effected through an automatic "sell to cover" transaction that did not represent a discretionary trade by the Reporting Person.
Each RSU represents the contingent right to receive one share of common stock of the Issuer.
The RSUs will vest in equal annual installments over the first four years after the vesting commencement date, August 16, 2021, subject to the Reporting Person's continued service to the Issuer on such vesting date.